• Company
• Will Roche’s lymphoma drug Columvi be discussed for reimb?
• by Eo, Yun-Ho Oct 28, 2024 05:53am

• Company
• "We have clinically proven Stelara for Koreans"
• by Moon, sung-ho Oct 28, 2024 05:53am

• Company
• Januvia generics occupy 17% of market in 1yr
• by Kim, Jin-Gu Oct 28, 2024 05:53am

• Company
• Will the ATTR-CM drug 'Vyndamax' receive reimb approval?
• by Eo, Yun-Ho Oct 25, 2024 05:49am

• Company
• K-new drugs Rosuzet·K-CAB dominate the prescription market
• by Chon, Seung-Hyun Oct 25, 2024 05:48am

• Company
• Biktarvy’s indication expanded to patients 6yrs and older
• by Whang, byung-woo Oct 24, 2024 05:52am

• Company
• Reimb of the dyslipidemia drug Leqvio at a halt?
• by Eo, Yun-Ho Oct 24, 2024 05:52am

• Company
• Moderna’s keyword for post-COVID vaccination is ‘RWE’
• by Whang, byung-woo Oct 23, 2024 05:50am

• Company
• "Multiple myeloma dynamics require changes to reimb strategy
• by Whang, byung-woo Oct 22, 2024 05:51am

• Company
• Will combination therapies for cancer be reimbursed in KOR?
• by Whang, byung-woo Oct 21, 2024 05:49am